Effect of Adrenaline Concentration on Intraoperative Hemodynamics of Liposuction Patients
1 other identifier
interventional
40
1 country
1
Brief Summary
Liposuction is a procedure that has emerged over the last 30 years as a method to remove subcutaneous fat for cosmetic purposes. Numerous liposuction techniques have been developed .Tumescent liposuction involves using large volumes of dilute local anesthetic and epinephrine to facilitate anesthesia and decrease blood loss. Questions remain about the appropriate dose of local anesthetic, the use of general anesthesia in liposuction, and the setting in which the chosen liposuction method is used. Adrenaline is the most commonly used vasoconstrictor, the recommended concentration in the tumescent solution is 0.25-1 mg/L depending on the tissue vascularity. In the more vascular tissues, the concentration is 1 mg/L and is decreased to 0.5 mg/L in the less vascular areas of the body. The dose should not exceed 50μg/kg. If the maximum dose is anticipated to exceed, the procedure should be done in several stages.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started May 2023
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2023
CompletedFirst Posted
Study publicly available on registry
April 21, 2023
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 15, 2023
CompletedDecember 26, 2023
December 1, 2023
6 months
April 10, 2023
December 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood pressure
Noninvasive Blood pressure will be recorded
4 hours
Secondary Outcomes (1)
Heart rate
4 hours
Study Arms (2)
Group A
ACTIVE COMPARATORTumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) Llidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter.
Group B
ACTIVE COMPARATORTumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter. Lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter.
Interventions
Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Eligibility Criteria
You may qualify if:
- ASA I patients
- scheduled for liposuction for abdomen and flanks and body contouring with liposuction
You may not qualify if:
- Bleeding disorders, anemia or hemoglobin level less than 11g/dl
- Cardiovascular diseases,
- Uncontrolled diabetes mellitus,
- Collagen disorders, and
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Al-Azhar Universitylead
- Benha Universitycollaborator
Study Sites (1)
Neveen Kohaf
Tanta, 11865, Egypt
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of Clinical Pharmacy
Study Record Dates
First Submitted
April 10, 2023
First Posted
April 21, 2023
Study Start
May 1, 2023
Primary Completion
October 15, 2023
Study Completion
October 15, 2023
Last Updated
December 26, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
data can be shared upon reasonable request from the corresponding author